LL-37 complexation with glycosaminoglycans in cystic fibrosis lungs inhibits antimicrobial activity, which can be restored by hypertonic saline.
There is an abundance of antimicrobial peptides in cystic fibrosis (CF) lungs. Despite this, individuals with CF are susceptible to microbial colonization and infection. In this study, we investigated the antimicrobial response within the CF lung, focusing on the human cathelicidin LL-37. We demonstrate the presence of the LL-37 precursor, human cathelicidin precursor protein designated 18-kDa cationic antimicrobial protein, in the CF lung along with evidence that it is processed to active LL-37 by proteinase-3. We demonstrate that despite supranormal levels of LL-37, the lung fluid from CF patients exhibits no demonstrable antimicrobial activity. Furthermore Pseudomonas killing by physiological concentrations of exogenous LL-37 is inhibited by CF bronchoalveolar lavage (BAL) fluid due to proteolytic degradation of LL-37 by neutrophil elastase and cathepsin D. The endogenous LL-37 in CF BAL fluid is protected from this proteolysis by interactions with glycosaminoglycans, but while this protects LL-37 from proteolysis it results in inactivation of LL-37 antimicrobial activity. By digesting glycosaminoglycans in CF BAL fluid, endogenous LL-37 is liberated and the antimicrobial properties of CF BAL fluid restored. High sodium concentrations also liberate LL-37 in CF BAL fluid in vitro. This is also seen in vivo in CF sputum where LL-37 is complexed to glycosaminoglycans but is liberated following nebulized hypertonic saline resulting in increased antimicrobial effect. These data suggest glycosaminoglycan-LL-37 complexes to be potential therapeutic targets. Factors that disrupt glycosaminoglycan-LL-37 aggregates promote the antimicrobial effects of LL-37 with the caveat that concomitant administration of antiproteases may be needed to protect the now liberated LL-37 from proteolytic cleavage.
Bergsson
Gudmundur
G
Department of Medicine, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin, Ireland. bergsson@here.is
Reeves
Emer P
EP
McNally
Paul
P
Chotirmall
Sanjay H
SH
Greene
Catherine M
CM
Greally
Peter
P
Murphy
Philip
P
O'Neill
Shane J
SJ
McElvaney
Noel G
NG
D000276:Adjuvants, Immunologic / Q000502:physiology; D000293:Adolescent; D000918:Antibody Specificity / Q000502:physiology; D023181:Antimicrobial Cationic Peptides / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000378:metabolism* / Q000502:physiology; D002402:Cathepsin D / Q000502:physiology; D002648:Child; D003550:Cystic Fibrosis / Q000201:enzymology / Q000276:immunology* / Q000378:metabolism* / Q000382:microbiology; D006025:Glycosaminoglycans / Q000378:metabolism* / Q000502:physiology; D006801:Humans; D006868:Hydrolysis; D019272:Leukocyte Elastase / Q000502:physiology; D008168:Lung / Q000201:enzymology / Q000276:immunology* / Q000378:metabolism* / Q000382:microbiology; D046911:Macromolecular Substances / Q000037:antagonists & inhibitors / Q000276:immunology / Q000378:metabolism; D008970:Molecular Weight; D053146:Myeloblastin / Q000378:metabolism; D009330:Nebulizers and Vaporizers; D011498:Protein Precursors / Q000378:metabolism; D011499:Protein Processing, Post-Translational; D012462:Saline Solution, Hypertonic / Q000008:administration & dosage / Q000494:pharmacology*; D012995:Solubility; D013183:Sputum / Q000201:enzymology / Q000276:immunology / Q000382:microbiology; D054804:Cathelicidins
D000276:Adjuvants, Immunologic; D023181:Antimicrobial Cationic Peptides; D006025:Glycosaminoglycans; D046911:Macromolecular Substances; D011498:Protein Precursors; D012462:Saline Solution, Hypertonic; D019272:Leukocyte Elastase; D053146:Myeloblastin; D002402:Cathepsin D; D054804:Cathelicidins